NCT01261000

Tissue Biomarker for Pegvisomant Action

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Cedars-Sinai Medical Center · Academic / Other
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Acromegaly is a disease of the pituitary gland that involves overproduction of growth hormone. Pegvisomant works by blocking binding of GH to receptors found in tissues throughout the body. Human studies have evaluated pegvisomant action by measuring reduction of IGF-I levels in the blood. However, no studies have evaluated the effects of blocking GH receptors in tissues. In this study, we will study tissue biomarkers for pegvisomant action in GH and IGF-I dependent signaling pathways in colon tissue of patients with acromegaly treated with pegvisomant.

Conditions

• Acromegaly

Interventions

Type	Name	Description
DRUG	Pegvisomant	Pegvisomant used as indicated

Timeline

• Start date: 2010-11-01
• Primary completion: 2013-03-01
• Completion: 2013-12-01
• First posted: 2010-12-16
• Last updated: 2017-08-22
• Results posted: 2017-08-22

Locations

1 site across 1 country: United States